209 related articles for article (PubMed ID: 23977117)
21. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
[TBL] [Abstract][Full Text] [Related]
22. The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma.
Liu X; Mangla R; Tian W; Qiu X; Li D; Walter KA; Ekholm S; Johnson MD
J Neurooncol; 2017 Dec; 135(3):553-560. PubMed ID: 28889246
[TBL] [Abstract][Full Text] [Related]
23. [Prognostic implication of alterations in epidermal growth factor receptor and MGMT in glioblastoma].
Zhang LY; Ge HJ; Wang LM; Zhao LH; Liu L; Zhang DJ; Cai YN; Lu DH; Piao YS
Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):186-191. PubMed ID: 30831643
[No Abstract] [Full Text] [Related]
24. Correlation of apparent diffusion coefficient values measured by diffusion MRI and MGMT promoter methylation semiquantitatively analyzed with MS-MLPA in patients with glioblastoma multiforme.
Sunwoo L; Choi SH; Park CK; Kim JW; Yi KS; Lee WJ; Yoon TJ; Song SW; Kim JE; Kim JY; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Chang KH
J Magn Reson Imaging; 2013 Feb; 37(2):351-8. PubMed ID: 23023975
[TBL] [Abstract][Full Text] [Related]
25. Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms.
Provenzale JM; York G; Moya MG; Parks L; Choma M; Kealey S; Cole P; Serajuddin H
AJR Am J Roentgenol; 2006 Oct; 187(4):1036-42. PubMed ID: 16985154
[TBL] [Abstract][Full Text] [Related]
26. Post-transcriptional regulation of O(6)-methylguanine-DNA methyltransferase MGMT in glioblastomas.
Ramakrishnan V; Kushwaha D; Koay DC; Reddy H; Mao Y; Zhou L; Ng K; Zinn P; Carter B; Chen CC
Cancer Biomark; 2011-2012; 10(3-4):185-93. PubMed ID: 22674304
[TBL] [Abstract][Full Text] [Related]
27. Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status.
Romano A; Calabria LF; Tavanti F; Minniti G; Rossi-Espagnet MC; Coppola V; Pugliese S; Guida D; Francione G; Colonnese C; Fantozzi LM; Bozzao A
Eur Radiol; 2013 Feb; 23(2):513-20. PubMed ID: 22875158
[TBL] [Abstract][Full Text] [Related]
28. T1-Weighted Dynamic Contrast-Enhanced MRI as a Noninvasive Biomarker of Epidermal Growth Factor Receptor vIII Status.
Arevalo-Perez J; Thomas AA; Kaley T; Lyo J; Peck KK; Holodny AI; Mellinghoff IK; Shi W; Zhang Z; Young RJ
AJNR Am J Neuroradiol; 2015 Dec; 36(12):2256-61. PubMed ID: 26338913
[TBL] [Abstract][Full Text] [Related]
29. Combined analysis of MGMT methylation and dynamic-susceptibility-contrast MRI for the distinction between early and pseudo-progression in glioblastoma patients.
Bani-Sadr A; Berner LP; Barritault M; Chamard L; Bidet CM; Eker OF; Hermier M; Guyotat J; Jouanneau E; Meyronet D; Gouttard S; D'Hombres A; Iziquierdo C; Honnorat J; Berthezène Y; Ducray F
Rev Neurol (Paris); 2019 Oct; 175(9):534-543. PubMed ID: 31208813
[TBL] [Abstract][Full Text] [Related]
30. Permeability measurement using dynamic susceptibility contrast magnetic resonance imaging enhances differential diagnosis of primary central nervous system lymphoma from glioblastoma.
Lee JY; Bjørnerud A; Park JE; Lee BE; Kim JH; Kim HS
Eur Radiol; 2019 Oct; 29(10):5539-5548. PubMed ID: 30877463
[TBL] [Abstract][Full Text] [Related]
31. MGMT gene promoter methylation in pediatric glioblastomas.
Srivastava A; Jain A; Jha P; Suri V; Sharma MC; Mallick S; Puri T; Gupta DK; Gupta A; Sarkar C
Childs Nerv Syst; 2010 Nov; 26(11):1613-8. PubMed ID: 20585787
[TBL] [Abstract][Full Text] [Related]
32. Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study.
Zawlik I; Vaccarella S; Kita D; Mittelbronn M; Franceschi S; Ohgaki H
Neuroepidemiology; 2009; 32(1):21-9. PubMed ID: 18997474
[TBL] [Abstract][Full Text] [Related]
33. Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas.
Yadav AK; Renfrow JJ; Scholtens DM; Xie H; Duran GE; Bredel C; Vogel H; Chandler JP; Chakravarti A; Robe PA; Das S; Scheck AC; Kessler JA; Soares MB; Sikic BI; Harsh GR; Bredel M
JAMA; 2009 Jul; 302(3):276-89. PubMed ID: 19602687
[TBL] [Abstract][Full Text] [Related]
34. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R
Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700
[TBL] [Abstract][Full Text] [Related]
35. Tumor blood flow from arterial spin labeling perfusion MRI: a key parameter in distinguishing high-grade gliomas from primary cerebral lymphomas, and in predicting genetic biomarkers in high-grade gliomas.
Yoo RE; Choi SH; Cho HR; Kim TM; Lee SH; Park CK; Park SH; Kim IH; Yun TJ; Kim JH; Sohn CH; Han MH; Chang KH
J Magn Reson Imaging; 2013 Oct; 38(4):852-60. PubMed ID: 23390061
[TBL] [Abstract][Full Text] [Related]
36. Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility.
Kim HS; Goh MJ; Kim N; Choi CG; Kim SJ; Kim JH
Radiology; 2014 Dec; 273(3):831-43. PubMed ID: 24885857
[TBL] [Abstract][Full Text] [Related]
37. The wavelet power spectrum of perfusion weighted MRI correlates with tumor vascularity in biopsy-proven glioblastoma samples.
Rotkopf LT; Wiestler B; Preibisch C; Liesche-Starnecker F; Pyka T; Nörenberg D; Bette S; Gempt J; Thierfelder KM; Zimmer C; Huber T
PLoS One; 2020; 15(1):e0228030. PubMed ID: 31971966
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Value of Dynamic Susceptibility Contrast-Enhanced and Diffusion-Weighted MR Imaging in Patients with Glioblastomas.
Çoban G; Mohan S; Kural F; Wang S; O'Rourke DM; Poptani H
AJNR Am J Neuroradiol; 2015 Jul; 36(7):1247-52. PubMed ID: 25836728
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
40. Uninterpretable Dynamic Susceptibility Contrast-Enhanced Perfusion MR Images in Patients with Post-Treatment Glioblastomas: Cross-Validation of Alternative Imaging Options.
Heo YJ; Kim HS; Park JE; Choi CG; Kim SJ
PLoS One; 2015; 10(8):e0136380. PubMed ID: 26296086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]